Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM

Moody Aldrich Partners LLC lowered its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 16.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,476 shares of the company’s stock after selling 9,934 shares during the period. Axsome Therapeutics accounts for approximately 1.2% of Moody Aldrich Partners LLC’s portfolio, making the stock its 16th largest holding. Moody Aldrich Partners LLC owned 0.10% of Axsome Therapeutics worth $6,252,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. AlphaQuest LLC bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $38,000. Ameritas Advisory Services LLC purchased a new position in Axsome Therapeutics during the 2nd quarter valued at about $77,000. Assetmark Inc. increased its position in shares of Axsome Therapeutics by 13.9% during the second quarter. Assetmark Inc. now owns 1,124 shares of the company’s stock valued at $117,000 after buying an additional 137 shares during the period. Allworth Financial LP lifted its holdings in shares of Axsome Therapeutics by 361.8% in the second quarter. Allworth Financial LP now owns 1,353 shares of the company’s stock worth $141,000 after buying an additional 1,060 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Axsome Therapeutics by 16.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,902 shares of the company’s stock worth $199,000 after buying an additional 270 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Axsome Therapeutics in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Axsome Therapeutics in a report on Wednesday. Guggenheim lifted their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright boosted their target price on Axsome Therapeutics from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $183.94.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: FDA granted priority review to AXS‑05 (Auvelity) for agitation in Alzheimer’s disease — a faster review path increases the chance of an earlier approval and near‑term commercial opportunity, which is the main catalyst cited for the stock’s strong jump. Read More.
• Positive Sentiment: Company announced FDA acceptance and priority review of a supplemental NDA for Auvelity (AXS‑05), confirming the agency’s formal review and prompting coverage across news services. Read More.
• Positive Sentiment: FDA provided formal pre‑NDA meeting minutes for AXS‑12 (reboxetine) in narcolepsy, keeping an NDA submission on schedule for January 2026 — another potential product that could expand Axsome’s CNS franchise. Read More.
• Neutral Sentiment: Analyst activity: Needham raised its price target to $169 and maintained a Buy rating, which signals analyst support even though the target sits below the intraday stock level — mixed signal on near‑term valuation. Read More.
• Neutral Sentiment: Several outlets and analyst summaries explain the stock move (coverage includes IBD, Schaeffer’s, AAII) — media amplification can extend buying momentum but does not change fundamentals by itself. Read More.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 10,558 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $1,071,193.22. This trade represents a 59.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 289,296 shares of company stock valued at $38,882,311 over the last ninety days. 22.30% of the stock is owned by corporate insiders.

Axsome Therapeutics Trading Up 22.8%

NASDAQ AXSM opened at $182.64 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock’s 50-day simple moving average is $145.19 and its two-hundred day simple moving average is $124.51. Axsome Therapeutics, Inc. has a twelve month low of $79.19 and a twelve month high of $184.40. The company has a market capitalization of $9.21 billion, a price-to-earnings ratio of -39.11 and a beta of 0.48.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The company’s quarterly revenue was up 63.2% on a year-over-year basis. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.